The IPO market remained active this past week as seven IPOs raised $2.1 billion. SPAC activity kept steady with 10 blank check IPOs raising $1.6 billion. New filers continued to pour into the IPO pipeline, with 12 IPOs and nine SPACs submitting initial...read more
MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $14. The company offered 0.7 million fewer shares than anticipated. ...read more
MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, announced terms for its IPO on Tuesday.The New York, NY-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At ...read more
US IPO Weekly Recap: DevOps platform GitLab leads a 7 IPO week
The IPO market remained active this past week as seven IPOs raised $2.1 billion. SPAC activity kept steady with 10 blank check IPOs raising $1.6 billion. New filers continued to pour into the IPO pipeline, with 12 IPOs and nine SPACs submitting initial...read more
Allogeneic T cell biotech MiNK Therapeutics prices downsized IPO at $12 low end
MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $14. The company offered 0.7 million fewer shares than anticipated. ...read more
Allogeneic T cell biotech MiNK Therapeutics sets terms for $52 million IPO
MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, announced terms for its IPO on Tuesday.The New York, NY-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At ...read more
US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week
...read more